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Sickle cell anemia (SCA) is a recessively inherited disease characterized by chronic hemolytic anemia, 
chronic inflammation, and acute episodes of hemolysis. Hydroxyurea (HU) is widely used to increase the 
levels of fetal hemoglobin (HbF). The objective of this study was to standardize and validate a method 
for the quantification of HU in human plasma by using ultra high performance liquid chromatography 
(UPLC) in order to determine the plasma HU levels in adult patients with SCA who had been treated 
with HU. We used an analytical reverse phase column (Nucleosil C18) with a mobile phase consisting 
of acetonitrile/water (16.7/83.3). The retention times of HU, urea, and methylurea were 6.7, 7.7, and 
11.4 min, respectively. All parameters of the validation process were defined. To determine the precision 
and accuracy of quality controls, HU in plasma was used at concentrations of 100, 740, and 1600 µM, with 
methylurea as the internal standard. Linearity was assessed in the range of 50-1600 µM HU in plasma, 
obtaining a correlation coefficient of 0.99. The method was accurate and precise and can be used for 
the quantitative determination of HU for therapeutic monitoring of patients with SCA treated with HU.
Uniterms: Sickle cell anemia/therapeutic monitoring. Hydroxyurea/quantification in human plasma. 
Ultra High Efficiency Liquid Chromatography/quantitative analysis.
A anemia falciforme (AF) é uma doença hereditária recessiva caracterizada por anemia hemolítica 
crônica, inflamação crônica e episódios agudos de hemólise. Hidroxiureia (HU) é amplamente utilizada 
para aumentar os níveis de hemoglobina fetal (Hb F). O objetivo consiste em padronizar e validar um 
método para a quantificação de HU no plasma humano utilizando Cromatografia Líquida de Ultra Alta 
Eficiência (UPLC), a fim de determinar os níveis de HU em pacientes adultos com AF, tratados com 
HU. Utilizou-se coluna analítica de fase inversa (Nucleosil C18), fase móvel constituída por acetonitrila/
água (16,7/83,3). Os tempos de retenção da HU, uréia e metiluréia foram respectivamente de 6,7, 7,7 e 
11,4 minutos. Definiram-se todos os parâmetros do processo de validação. Para determinar a precisão e 
exatidão dos controles de qualidade utilizaram-se concentrações de 100, 740 e 1600 mM de HU no plasma, 
empregando como padrão interno a metiluréia. A linearidade foi avaliada no intervalo de 50-1600 mM de 
HU no plasma, obtendo-se coeficiente de correlação de 0,99. O método foi considerado exato e preciso e 
pode ser realizado com o propósito de determinação quantitativa de HU para monitorização terapêutica 
de pacientes com AF tratados com esse fármaco.
Unitermos: Anemia falciforme/monitorização terapêutica. Hidroxiuréia/quantificação em plasma 
humano. Cromatografia Líquida de Ultra Alta Eficiência/análise quantitativa.
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INTRODUCTION
Hydroxyurea (HU), a structural analogue of urea, 
inhibits the activity of ribonucleotide reductase. It has 
been used clinically since the 1960s, primarily in the 
treatment of Chronic Myeloid Leukemia, acting as a 
cytotoxic, mutagenic, and recombinogenic antineoplastic 
agent with specificity to the S phase of the cell cycle 
(preventing cell division) and with specific action on 
ribonucleotide reductase (interfering with the conversion 
of ribonucleotides to deoxyribonucleotides) (Bachir et al., 
2007; Ballas, 2012). Since 1998, HU became part of the 
therapeutic program for patients with sickle cell anemia 
(SCA), and was the first drug with proven clinical efficacy 
in the treatment of this disease. HU is commercially 
available (Hydréia®) as a 500 mg tablet and the prescribed 
dosage ranges from 15 - 25 mg/kg /day. Response to 
HU treatment is variable, since the therapeutic response 
is associated with the clinical severity of the factors 
modulating SCA, including the concentration of fetal 
hemoglobin (HbF) in groups with haplotype beta globin, 
co-association with alpha-thalassemia, and the presence 
of polymorphisms for XmnI, BCL11A, and HBS1L-
MYB (Cokic et al., 2008). Moreover, the variability of 
the response may be associated with variations in drug 
metabolism (Cançado et al., 2009).
The efficacy of HU treatment for SCA is generally 
attributed to its ability to enhance HbF, reducing the 
intra-erythrocytic polymerization of HbS in conditions of 
deoxygenation. However, HU also promotes a reduction 
in the number of neutrophils, reduced expression of 
erythrocyte adhesion molecules, and increased synthesis 
and bioavailability of nitric oxide by the activation of 
guanylyl cyclase and subsequent increase in cyclic GMP 
(Friedrisch et al., 2008; Gladwin et al., 2002).
Besides increasing the concentration of HbF, these 
mechanisms confer benefits such as reduced hemolysis, 
decreased adhesion of erythrocytes, leukocytes, and 
platelets to the vascular endothelium, and vasodilatation, 
contributing to a reduction in vaso-occlusive and 
inflammatory complications (Lettre et al., 2008).
Despite its proven clinical efficacy, many aspects 
of the role of HU in patients with SCA remain unclear, 
such as optimal therapeutic dose, mechanism of drug 
action, the intense variability in therapeutic response, and 
cytotoxicity and genotoxicity. The carcinogenic potential 
of HU is not well established; some studies associate 
HU with an increased risk of leukemia in patients with 
myeloproliferative disorders (Manouilov, McGuire, Gwilt, 
1998; Silva, Shimauti, 2006).
In order to establish a standard treatment regimen 
based on the pharmacokinetics of HU in patients with 
SCA, it is necessary to develop and validate a method 
for the quantification of HU in human plasma. This 
method was developed based on the methods described 
by Manouilov et al. (1998) and Bachir et al. (2007). We 
performed modifications in the sample preparation, using 
a smaller volume of plasma. For the colorimetric reaction, 
no commercial kits were used, while an Ultra High 
Performance Liquid Chromatography with diode detector 
(UV) was employed as it affords a higher resolution 
of the chromatograms analyzed. These modifications 
in the method de Manouilov (1998) and Bachir et al. 
(2007) resulted in a method with increased sensitivity, 
lower quantification limit, and reduced time of analysis; 
nevertheless, its validation is necessary (Manouilov, 
McGuire, Gwilt, 1998; Bachir et al., 2007).
MATERIAL AND METHODS
Chemicals
Hydroxyurea (>98%; 04/04/2013), methylurea 
(97%; 04/04/2013) (internal standart), diacetyl monoxime 
(C4H7NO2), tiosemicarbazide (CH5N3S) and ferric chloride 
(FeCl3) were purchased from SIGMA® (St. Louis, MO, 
USA). Sodium chloride (NaCl) from LABSYNTH® (SP, 
Brazil), sulfuric acid from Cromato Produtos Químicos 
Ltda (SP, Brazil), orthophosporic acid from TEDIA® 
(RJ, Brazil), trichloroacetic acid and acetonitrile were 
purchased from VETEC® (RJ, Brazil). Plasma standards 
were obtained from Hemocenter of the State of Ceará, 
Brazil.
Solutions
A stock solution of hydroxyurea was prepared in 
acetonitrile/water (1:1) at a concentration of 10,000 µM, 
which was dissolved in acetonitrile/water (1:1) to obtain 
concentrations of 8000, 6000, 3200, 2000, 1000, 500, and 
250 µM. The standard solutions were stored in a 4 °C, and 
after comparison with the test solutions prepared freshly 
observed stable for 20 days. The methylurea solution 
used as internal standard was prepared at a concentration 
of 15.5 mM.
The colorimetric solution (A) was prepared by 
combining 0.2 g thiosemicarbazide, 0.9 g sodium chloride, 
and 0.1 g diacetyl monoxime in distilled water qsp 
100 mL. The acid solution (B) was prepared by adding 
6 mL sulfuric acid (H2SO4) and 1 mL phosphoric acid to 
80 mL of distilled water, dissolving 0.01 g ferric chloride 
in this solution, and filling to 100 mL with distilled water.
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Chromatographic conditions
The equipment Ultra High Performance Liquid 
Chromatography (UPLC) consists of a pumping system 
with diode array detector (PDA) (Accela® Thermo 
Scientific) and data acquisition system ChromQuest 
5.0 (Thermo Scientific®). Compounds were separated 
by reverse-phase chromatography on analytical column 
NUCLEOSIL C18, 250_4.6 column (5 µm particle size) 
from Phenomenex® and pre-column C18 (4x30 mm). The 
mobile phase used was acetonitrile/water (16.7 / 83.3) flow 
of 1 mL/min, wavelength 440 nm.
Sample preparation
In a 10 mL tube, 400 µL aliquots of plasma from 
patients treated with hydroxyurea were combined with 
80 µL of 15.5 mM methylurea (internal standard) and 
800 µL of 20% trichloroacetic acid to precipitate proteins. 
After vortexing (30 s) and centrifugation (3500 rpm for 
10 min), 1000 µL of supernatant were transferred to another 
tube, and 1000 µL of solution A (colorimetric) and 1000 µL 
of solution B (acid reagent) were added. The mixture was 
heated in a water bath to 100 °C for 10 min and then cooled 
to 4 °C for 10 min. A 25 µL sample of the reaction product 
was subjected to chromatographic analysis.
Calibration curve
To construct the calibration curve (performed in 
triplicate), 400 µL aliquots of human plasma blanks 
(those not treated with hydroxyurea) were enriched with 
100 µL of an appropriate concentration of the working 
standard solution to obtain hydroxyurea concentrations 
of 50, 100 200, 400, 740, 1200, and 1600 µM in plasma; 
these concentrations were chosen based on the expected 
plasma levels of HU and comprised seven data points, 
including the quantification limit. The internal standard 
(80 µL, 15.5 mM) was added to each solution, which was 
then subjected to the process of sample preparation and 
chromatographic analysis as described above.
The linear regression equations and correlation 
coefficients were obtained by dividing the peak area 
of hydroxyurea by the area of the internal standard 
(hydroxyurea/IS), plotted as a function of their 
concentrations. The acceptance criteria for calibration 
curves included a linear correlation coefficient greater 
than or equal to 0.99, a deviation less than or equal to 
20% compared to the nominal concentration for the lower 
limit of quantification, and a standard deviation less than 
or equal to 15% over nominal concentration for the other 
concentrations of the calibration curves.
Validation
The validation process was performed in October 
2012 in accordance with Resolution RDC no 27 of 
17/05/2012, the Ministry of Health – National Health 
Surveillance Agency, which is also in accordance with the 
Guidance for Industry – Bioanalytical Method Validation, 
2013. (Brazil, 2012; FDA, 2013)
Limit of quantification
The limit of quantification was defined as the lowest 
concentration quantified with precision and accuracy 
with relative standard deviation (RSD) and coefficient of 
variation (CV%) ± 20%. Samples of human plasma were 
enriched with hydroxyurea to yield concentrations as low 
as 50 µM. The samples were analyzed in quintuplicate.
Linearity
Linearity was assessed at the concentrations 
used in the calibration curve, by gradually increasing 
the concentration to 1600 µM hydroxyurea in plasma. 
After. we determined the linear regression equations and 
correlation coefficients.
Selectivity
The interference from endogenous components of 
plasma was assessed by the analysis of plasma aliquots 
obtained from six different individuals who were not 
treated with hydroxyurea.
Precision and accuracy
To determine precision and accuracy, quality 
controls were used at concentrations of 100, 740, and 
1600 µM of hydroxyurea in plasma.
To evaluate precision within assays, 5 aliquots were 
analyzed for each control on a single day, or across a 
single calibration curve. To evaluate the precision between 
assays, aliquots were analyzed in quintuplicate, with 
quality controls on three consecutive days. Precision was 
expressed as coefficient of variation (CV%), assuming no 
values of ± 15% (fifteen percent).
Accuracy within and between assays was also 
evaluated using the experimental results from the precision 
evaluations. The accuracy was expressed through the 
Relative Standard Error (RSE), not including values 
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outside the range of ±15% (fifteen percent) of the nominal 
value.
RSE =
Average concentration experimental – nominal value
nominal value
× 100
Clinical and experimental protocol
We analyzed 22 adult patients (5 men and 17 
women, aged between 20 and 40 years) with clinical and 
laboratory diagnoses of SCA, confirmed by molecular 
biology, with a baseline treatment with hydroxyurea for 
over a year, accompanied at the outpatient clinic of a 
university hospital in Fortaleza, Ceará, Brazil. Baseline 
determination was based on the criteria described by Ballas 
(2012): absence of painful episodes and/or concurrent 
illnesses such as infections or inflammation in the four 
weeks preceding the study; no hospital admissions in the 
2-3 days prior to study; and absence of blood transfusion 
in the four months preceding the study. The exclusion 
criteria included an absence of molecular diagnosis of 
SCA, pregnancy, presence of renal or liver failure, or 
smoking (Ballas, 2012).
Informed consent was obtained from all patients 
(or from the responsible person) prior to enrollment 
into the study, and the study protocol was submitted to 
and approved by the Ceará Federal University Ethics 
Committee under protocol N° 110.10.10.
Venous blood was collected in containers containing 
the anticoagulant heparin, 2.5 h after drug intake. Plasma 
samples for chromatographic analysis were obtained by 
centrifugation of the blood samples at 4000 rpm for 10 
min and were stored at -80 °C until the time of analysis.
Plasma concentrations of hydroxyurea in the patients 
tested was calculated using the calibration curves.
RESULTS
Analysis of hydroxyurea in plasma
Figures 1 and 2 show the chromatographic analysis 
of a plasma blank enriched with solutions of hydroxyurea 
and methylurea (internal standard) and plasma from 
a patient with sickle cell disease being treated with 
hydroxyurea (1000 mg/day), respectively. It was observed 
that the retention times of hydroxyurea, urea, and 
methylurea were 6.763 min, 7.778 min, and 11.472 min, 
respectively.
FIGURE 1 - Chromatogram of plasma enriched with 1200 µM hydroxyurea and 15.5 mM methylurea (internal standard).
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Calibration Curve
The Figure 3 shows the calibration curve in the range 
of 50-1600 mM of hydroxyurea in human plasma. The 
correlation coefficient was 0.9908.
Validation of method
Table I shows the results of the validation of the 
analytical method of hydroxyurea in human plasma. The 
FIGURE 2 - Chromatogram of plasma from patients undergoing SCA therapy with hydroxyurea 1000 mg/day enriched with 
15.5 mM methylurea (internal standard).
FIGURE 3 - Calibration curve of HU in the range of 50-1600 µM 
hydroxyurea in human plasma.
calculated correlation coefficient (r) indicates a linear 
relationship between the area and the concentration 
of hydroxyurea. Method was validated according to 
national guidelines for the validation of analytical and 
bioanalytical methods (RDC 27/2012) and to the ICH 
(International Conference on Harmonisation) guidelines 
for bioanalytical method validation (ANVISA, 2012; 
International Conference on Harmonisation, 2001).
Analysis of patients
We analyzed 22 adult patients (5 men and 17 women, 
aged between 20 and 40 years) with clinical and laboratory 
diagnoses of SCA treated with hydroxyurea for over one 
year, at doses of 500 mg/day (1 patient), 1000 mg/day (18 
patients), and 1500 mg/day (3 patients), and the average 
HU concentrations in plasma collected from these dosage 
groups were 98.31 µM, 190.88 µM, and 302.71 µM, 
respectively.
DISCUSSION
Hydroxyurea therapy in patients with sickle cell 
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anemia (SCA) has a proven clinical and laboratory 
efficacy. Administered in concentrations of 15 to 
25 mg/kg/day, it can induce an increase of 10 to 40% of 
HbF. However, the variability in therapeutic response is 
high and may be associated with pharmacogenetic factors 
that lead to phenotypic characteristics of fast or slow 
metabolizers. Given this variation, the search for a safe 
therapeutic use that avoids the cyto- and genotoxicity of 
the drug through a standard regimen based on therapeutic 
monitoring is essential (Steinberg et al., 2010; Veale et al., 
1988). Thus, the quantification method of hydroxyurea in 
human plasma by UPLC with diode detector (UV) was 
developed in order to follow up patients treated with this 
drug. It was developed from the methods of Manouilov 
et al. (1998) and Bachir et al. (2007) and is based on 
the formation of a color reaction between hydroxyurea 
and solutions A (thiosemicarbazide + sodium chloride + 
diacetyl monoxime) and B (sulfuric acid + phosphoric 
acid + ferric chloride) (Manouilov, McGuire, Gwilt et al., 
1998; Bachir et al., 2007).
While developing the method, the optimal 
wavelength was chosen by performing a “scan” of 
wavelengths between 300 and 600 nm. A wavelength of 
440 nm was identified as having the highest absorption. 
To choose the best mobile phase, adjustments were made 
in the proportions of acetonitrile/water, and the analysis 
time obtained was of 13 min, a reduction of 50% compared 
to the method of Bachir et al. (2007), which used 16.7% 
acetonitrile (Bachir et al., 2007).
The plasma sample was treated by an initial 
precipitation of proteins (clean-up) using trichloroacetic 
acid instead of perchloric acid, as described by Bachir et 
al. and Manouilov et al., thereby reducing interference by 
endogenous substances. After this step, the colorimetric 
reaction was carried out (Manouilov, McGuire, Gwilt, 
1998; Bachir et al., 2007).
The specificity of the method was confirmed when 
it was observed that the retention times of hydroxyurea, 
urea, and methylurea were 6.763 min, 7.778 min, 
and 11.472 min, respectively, with no interference to 
methylurea (internal standard) or urea from endogenous 
substances at high concentrations in the plasma. The 
calibration curve in the concentration range of 50-1600 µM 
hydroxyurea in plasma was selected from therapeutic 
concentrations observed in the dosages of 15 mg/kg/day 
to 30 mg/kg/day of hydroxyurea.
The calibration curve in the concentration range of 
50-1600 µM hydroxyurea in plasma was selected from 
therapeutic concentrations observed in the dosages of 
15 mg/kg/day to 30 mg/kg/day of hydroxyurea.
The method was deemed precise and accurate, using 
quality controls at low, middle, and high concentrations of 
100 µM, 740 µM, and 1200 µM, respectively, presenting 
a quantification limit, selectivity, precision, and accuracy 
compatible with application in the analysis of hydroxyurea 
in patients treated with a multiple dose regimen. Moreover, 
the method was considered to be linear, since the obtained 
correlation coefficient was greater than 0.99.
We note that, in the validation process, hydroxyurea, 
TABLE I - Confidence limits for the method of analysis of 
hydroxyurea
Hydroxyurea
Linearity (50-1600 µM) 
Line Equation 
R
 
y = 0.00029x - 0.00285 
0.99084
Limit of Quantification (50 µM) 
Precision (CV%, n = 5) 
Accuracy (RSE, n = 5)
 
13.45 
4.96
Precision within assays 
(CV%, n = 5) 
 100 µM  
740 µM  
 1200 µM 
 
 
2.22 
2.52 
4.52
Precision between assays 
(CV%, n = 15) 
 100 µM  
 740 µM  
 1200 µM
 
 
6.39 
7.04 
10.38
Accuracy within assays 
(RSE%, n=5) 
100 µM  
740 µM 
1200 µM 
 
 
0.80 
-4.26 
-5.94
Accuracy between assays 
(RSE%, n = 15) 
100 µM  
740 µM 
1200 µM 
 
 
-1.35 
-2.50 
3.32 
CV = Coefficient of variation [(SD/média)x 100];
r = linear correlation coefficient.
RSE= [(Caverage experimental-C added )/C added ]x100
TABLE 2 - Average concentrations of HU in patients with SCA
Treatment dose 
(mg/day)
Average 
Concentration 
(µM) ±SD
N
500 
1000 
1500
98,31±0 
190,88 ± 100,7433 
302,71± 212,6223
1 
3 
18
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methylurea standard solution, and solutions A and B used 
in colorimetric reaction all showed a stability of greater 
than 20 days. The color reaction product was unstable after 
5 h of reaction, with a decrease in absorbance, and plasma 
samples containing hydroxyurea are unstable for a period 
longer than six months even when stored at -80 °C.
The mean concentrations obtained 2.5 h after 
ingestion of hydroxyurea in doses of 500 mg, 1000 mg, 
and 1500 mg per day were 98.31, 190.88, and 302.71 µM, 
respectively, compatible with the pharmacokinetics of the 
drug, whose maximum concentration (Cmax) is 793.75 µM 
for a dose of 2000 mg/day with maximum time (Tmax) 
of 1.22 h (Ware et al., 2011; Rodriguez et al., 1998). 
However, it should be noted that there are phenotypic 
differences in drug metabolism; in rapid metabolizers, 
Cmax is achieved 15 to 30 min after ingestion, whereas 
in poor metabolizers Cmax is achieved 60 to 120 min 
after ingestion (Ware et al., 2011; Rodriguez et al., 1998). 
Therefore, for therapeutic monitoring of patients treated 
with HU, the ideal collection time would be 30 min and 
1.5 h after drug intake.
The results of this study demonstrate that the method 
presents highly linear correlation and can be used for 
quantitative determination of hydroxyurea for therapeutic 
monitoring in patients with sickle cell anemia.
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